SolutionMRP Under Process
Official PMBI MRP is being updated for catalog code 2112.
Locate Jan Aushadhi KendraClinical Overview
Ketorolac Tromethamine Ophthalmic Solution (0.4% w/v) is a topical ocular NSAID on the WHO Model List framework. It inhibits ocular cyclooxygenase to block ocular prostaglandin synthesis, preventing intraoperative miosis and relieving postoperative ocular inflammation and photophobia following cataract surgery and refractive surgery.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Instill one drop into the affected eye(s) four times daily starting 24 hours prior to cataract surgery and continuing for 2 weeks postoperatively. Remove contact lenses before instillation.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Transient stinging, burning upon instillation, ocular hyperemia. Rare/Severe: Corneal ulceration, keratitis, and corneal melt/perforation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
For ophthalmic use only. Prolonged topical use (>2 weeks) increases risk of corneal epithelial breakdown and corneal perforation. Discontinue immediately if corneal melt develops.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.
Ketorolac Tromethamine Tablets 10mg
Ketorolac Tromethamine Tablets / Dispersible Tablets (10mg) is an oral pyrrolizine carboxylic acid NSAID on the WHO Model List framework for short-term continuation therapy following IV ketorolac. It exerts potent analgesic and moderate anti-inflammatory action via cyclooxygenase inhibition. Indicated ONLY as continuation therapy to parenteral ketorolac for moderate-to-severe acute postoperative pain, for a total combined duration not exceeding 5 days.
Ketorolac Injection 30mg per ml
Ketorolac Tromethamine Injection (30mg/ml) is a parenteral pyrrolo-pyrrole NSAID on the WHO Model List of Essential Medicines. It provides powerful non-opioid analgesia comparable to therapeutic doses of morphine by potently inhibiting COX-1 and COX-2 without causing respiratory depression, sedation, or bowel hypomotility. Indicated for short-term management (up to 5 days only) of moderate-to-severe acute postoperative surgical pain.
Ketorolac Tromethamine Dispersible Tablet 10 mg
Ketorolac Tromethamine Tablets / Dispersible Tablets (10mg) is an oral pyrrolizine carboxylic acid NSAID on the WHO Model List framework for short-term continuation therapy following IV ketorolac. It exerts potent analgesic and moderate anti-inflammatory action via cyclooxygenase inhibition. Indicated ONLY as continuation therapy to parenteral ketorolac for moderate-to-severe acute postoperative pain, for a total combined duration not exceeding 5 days.
Ketorolac (0.5% W/V) + Moxifloxacin (0.5% W/V) Eye Drops
Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.